The Enterprise Value as of September 2024 (TTM) for Halozyme Therapeutics, Inc. (HALO) is 8.85B

According to Halozyme Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 8.85B. This represents a change of 31.12% compared to the average of 6.75B of the last 4 quarters.

Halozyme Therapeutics, Inc. (HALO) Historical Enterprise Value (quarterly & annually)

How has HALO Enterprise Value performed in the past?

The mean historical Enterprise Value of Halozyme Therapeutics, Inc. over the last ten years is 4.04B. The current 8.85B Enterprise Value has changed 21.81% with respect to the historical average. Over the past ten years (40 quarters), HALO's Enterprise Value was at its highest in in the December 2022 quarter at 8.97B. The Enterprise Value was at its lowest in in the September 2014 quarter at 1.13B.

Halozyme Therapeutics, Inc. (HALO) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Halozyme Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Halozyme Therapeutics, Inc. (HALO) Average Enterprise Value

How has HALO Enterprise Value performed in the past?

The current Enterprise Value of Halozyme Therapeutics, Inc. (HALO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Halozyme Therapeutics, Inc. (HALO) Enterprise Value vs. Peers

How is HALO’s Enterprise Value compared to its peers?

Halozyme Therapeutics, Inc.’s Enterprise Value is greater than Agios Pharmaceuticals, Inc. (2.44B), less than Insmed Incorporated (12.34B), greater than Cerevel Therapeutics Holdings, Inc. (8.24B), greater than Ultragenyx Pharmaceutical Inc. (5.53B), less than BioMarin Pharmaceutical Inc. (16.13B), less than Seagen Inc. (42.84B), less than Alnylam Pharmaceuticals, Inc. (33.42B), greater than Exelixis, Inc. (7.21B), greater than Alector, Inc. (460.58M), less than Legend Biotech Corporation (10.04B), greater than Ascendis Pharma A/S (6.58B), greater than Cytokinetics, Incorporated (6.96B), greater than Edgewise Therapeutics, Inc. (1.60B), greater than Apellis Pharmaceuticals, Inc. (5.11B), greater than Blueprint Medicines Corporation (6.16B), less than BeiGene, Ltd. (19.49B), greater than Inhibrx, Inc. (-6681886.00), greater than Protagonist Therapeutics, Inc. (2.10B), greater than DICE Therapeutics, Inc. (2.21B), greater than Larimar Therapeutics, Inc. (486.93M), greater than Viridian Therapeutics, Inc. (813.50M),

Build a custom stock screener for Halozyme Therapeutics, Inc. (HALO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Halozyme Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Halozyme Therapeutics, Inc. (HALO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Halozyme Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.